Trump threatens 200% tariffs on imported generic drugs

Donald Trump threatened on July 22, 2026 to impose tariffs of up to 200% on imported generic medicines to encourage onshore production, a proposal that would directly affect trade flows in pharmaceuticals and raise concerns for major exporting countries.

200% tariff on generics

The announcement frames tariffs as a tool to rebuild US manufacturing for generics; the statement did not include implementation details or a timetable. Officials have not published an official tariff schedule, and reaction from markets and buyers remains pending.

Policy analysts say sharply higher import levies would raise costs for hospitals, insurers and patients that rely on imported generics, and could prompt exporters to seek exemptions or alternative markets. The move puts pressure on countries that supply large volumes of low-cost medicines to the United States and could trigger trade disputes if enacted.

Trade officials and industry participants will watch whether the administration follows with a formal proposal and whether any exemptions are carved out for essential medicines. If measures proceed, supply-chain adjustments and higher procurement costs are plausible near-term outcomes for health systems that depend on imports.

Markets and exporters should monitor developments closely; watch for any formal tariff proposal or rulemaking by July 29, 2026 for the next clear policy signal.